FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Neffy Broadcast Ad False or Misleading: OPDP

[ Price : $8.95]

An FDA Untitled Letter cautions ARS Pharmaceutical about false or misleading claims for its Neffy nasal spray.

Public Citizen Sues Over Drug Price Deals

[ Price : $8.95]

Public Citizen asks a federal court to order the Trump administration to make public the terms of drug pricing deals it signed wit...

FDA Warns HIV Testing Companies on Collection Devices

[ Price : $8.95]

An Akin legal update says FDAs recent issuance of Warning Letters to four direct-to-consumer testing companies over the use of una...

FDA Cites Sterile Compounding Lapses at Nubratori

[ Price : $8.95]

FDA cites Nubratori Inc. for multiple manufacturing and contamination-control deficiencies following a December inspection of the ...

HHS OIG Outlines Safe Harbor for DTC Drug Sales

[ Price : $8.95]

HHS Office of Inspector General issues new guidance clarifying when pharmaceutical manufacturers can sell prescription drugs direc...

CGMP Issues at Malaysias Fulijaya Manufacturing

[ Price : $8.95]

FDA warns Malaysias Fulijaya Manufacturing about CGMP violations in its production of finished drugs.

Using AI in Tumor Assessment

[ Price : $8.95]

A Friends of Cancer Research white paper explores the emerging role of AI-enabled tumor assessment tools and the framework needed ...

Roche Reports Positive Phase 2 Data for Obesity Drug

[ Price : $8.95]

Roche says its experimental dual GLP-1/GIP receptor agonist CT-388 delivered substantial and statistically significant weight loss...

FDA Enforcement Year in Review

[ Price : $8.95]

A Ropes & Gray year-end review examines significant changes in FDA and Justice Department enforcement actions pertaining to regula...

FDA Lifts Clinical Hold on Intellias Phase 3 Trial

[ Price : $8.95]

FDA lifts a clinical hold on Intellia Therapeutics MAGNITUDE-2 Phase 3 trial evaluating nexiguran ziclumeran for patients with her...